MiR-27b directly targets Rab3D to inhibit the malignant phenotype in colorectal cancer
Metrics: PDF 1193 views | HTML 1513 views | ?
Yang Luo1,*, Shi-Yong Yu2,*, Jian-Jun Chen1,*, Jun Qin1, Yi-Er Qiu1, Ming Zhong1 and Min Chen1
1Department of Gastrointestinal Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, P.R. China
2Department of General Surgery, Shanghai Pudong New Area People's Hospital, Shanghai 201200, P.R. China
*These authors contributed equally to this work
Min Chen, email: [email protected]
Ming Zhong, email: [email protected]
Keywords: colorectal cancer; miR-27b; Rab3D; prognosis
Received: October 18, 2017 Accepted: December 01, 2017 Published: December 12, 2017
MiRNAs, as oncogenes or as anti-oncogenes, play critically regulated roles in the initiation and progression of colorectal cancer at posttranscriptional level. However, the underlying functions of miR-27b in colorectal cancer remain largely unexplored. Here, we demonstrated miR-27b is significantly down-regulated in colorectal cancer tissues, and decreased miR-27b expression was closely associated with shorter overall survival of patients with colorectal cancer. By gain- and loss-of-function studies, we showed miR-27b remarkably suppressed cell proliferation and invasion of colorectal cancer. Furthermore, luciferase reporter assay identified Rab3D was the direct functional target of miR-27b. And Rab3D partly reversed the suppression of cell proliferation and invasion caused by miR-27b mimics. Finally, the animal experiment showed miR-27b plays a crucial role on colorectal cancer progression by targeting Rab3D. Taken together, our study implied miR-27b inhibits cell growth and invasion by targeting Rab3D, and miR-27b is a potential biomarker for prognosis and therapeutic target in colorectal cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.